Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity

This publication has 57 references indexed in Scilit:

• Allele-Specific p53 Mutant Reactivation
  Cancer Cell, 2012
• Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds
  JBIC Journal of Biological Inorganic Chemistry, 2011
• A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study
  Cancer Chemotherapy and Pharmacology, 2011
• Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti‐tumour efficacy
  British Journal of Pharmacology, 2011
• Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment
  Biochemical Pharmacology, 2011
• A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo
  Free Radical Biology and Medicine, 2011
• Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
  Journal of Clinical Oncology, 2008
• K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
  New England Journal of Medicine, 2008
• Ni(II), Cu(II), and Zn(II) Diethyldithiocarbamate Complexes Show Various Activities Against the Proteasome in Breast Cancer Cells
  Journal of Medicinal Chemistry, 2008
• Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
  Proceedings of the National Academy of Sciences, 2005